Deliver Your News to the World

Basilea Focuses on Commercialization


Basilea Pharmaceutica Ltd. (SWX:BSLN) announced today a new management structure reflecting the company’s high priority on commercializing its pre-registrations drugs.
Basilea has two investigatory drugs for high medical need currently undergoing regulatory review and a third compound in phase III testing. In anticipation of two potential product launches in the next 12 months, Basilea’s Board of Directors has implemented a more focused management structure to optimally support the company’s commercialization efforts.

“Successful commercialization of our innovative molecules is key to our future success. In order to achieve our goal we have restructured the management team to focus on this objective. We intend to fully focus and align our organization to build a profitable and sustainable business”, commented Basilea Pharmaceutica CEO, Anthony Man.

The management committee, headed by Dr. Man, will consist of a representative from the following functions: Commercial Operations, Finance, Technical Operations/Supply Chain plus Development and Research. There are no changes in personnel involved in the new structure.
About Basilea
Basilea Pharmaceutica Ltd. is an integrated biopharmaceutical company headquartered in Basel, Switzerland, listed on the SWX Swiss Exchange (SWX:BSLN). Basilea is currently focused on the research, development and commercialization of new antibacterial, antifungal and dermatology drugs in the hospital and specialty care setting. The company owns a diversified product portfolio including two products in pre-registration and a third in phase III clinical development. Basilea is building a sustainable hospital and specialty biopharmaceutical business.
This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For further information, please contact:

General Information

Investor Relations

Dr. Barbara Zink
This press release can be downloaded from


This news content was configured by WebWire editorial staff. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.